SmithKline Beecham Infanrix
FDA's Vaccines and Related Biological Products Advisory Committee will meet Sept. 14 to review data relating to a fifth successive dose of SmithKline's DTaP vaccine. The committee will also hear an update on Wyeth-Ayerst's Rotashield rotavirus vaccine and a report on the recent workshops on thimerosal in vaccines and cell substrates for vaccine development (1see related story, p. 23)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth